BioPharmSignal logoBioPharmSignal

Biotech News

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesCompany update

A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec.

Related news

ADPTAdaptive Biotechnologies2026-06-15 20:10 EST

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

View all latest news

Adaptive Biotechnologies

Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The...

Recent company news

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

ADPTAdaptive Biotechnologies2026-07-09 20:05 EST

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

ADPTAdaptive Biotechnologies2026-06-30 12:30 EST

Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

ADPTAdaptive Biotechnologies2026-06-17 10:00 EST

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

ADPTAdaptive Biotechnologies2026-06-15 20:10 EST

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Stock data

Close
25.99 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States